To validate the pathological relevance of our in vitro-derived ‘SOC sensitivity’ score and its association with the processes we identified, we re-analyzed a neo-adjuvant treated ER+ breast cancer patient dataset, GSE9320422 (Supplementary Fig. 4a). This evidence concerns the gene ESR1 and breast carcinoma.